PDCD1 and neoplasm: Although the toxicity and tolerability profile of anti-PD-1/PD-L1 in clinical trials is promising [17, 49], our study was limited by the short duration of treatments as enforced by the rapid tumor growth in our model making it difficult to determine possible toxicity.